Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group
2013; Wiley; Volume: 61; Issue: 3 Linguagem: Inglês
10.1002/pbc.24605
ISSN1545-5017
AutoresBrenda J. Weigel, Suman Malempati, Joel M. Reid, Stephan D. Voss, Steven Y. Cho, Helen X. Chen, Mark Krailo, Doojduen Villaluna, Peter C. Adamson, Susan M. Blaney,
Tópico(s)Lymphoma Diagnosis and Treatment
ResumoThis phase 2 study was designed to assess the efficacy of single agent cixutumumab (IMC-A12) and gain further information about associated toxicities and pharmacodynamics in children, adolescents, and young adults with recurrent or refractory solid tumors.
Referência(s)